“For a patient with metastatic cancer, to think that there is a cancer treatment in development that could treat metastasis, and is potentially nontoxic… that’s life changing”
Our goal is to successfully treat metastatic disease by inactivating the survival mechanism of metastatic tumor cells. TransCode is developing a platform of targeted therapies with the goal of achieving lifelong regression of metastatic disease with no recurrence.
and nearly 9 million people will lose their life to cancer. Cancer continues to be one of the leading causes of morbidity and mortality worldwide, but therapeutic innovation based on improved understanding of disease biology and translational research have considerably changed the treatment paradigm for many cancers.1 However, despite the many therapies and the billions of dollars spent each year, existing cancer treatments are only incrementally improving patient outcomes for late stage disease. It is now widely known that nine out of ten cancer deaths are due to metastasis and not the primary tumors from which they originate.
that we have termed “metastamiR dependence”. Our research shows that metastatic tumor cells cannot survive without the overexpression of a specific non-coding RNA molecule, microRNA-10b, which regulates the viability of metastatic tumor cells.
